Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

104.97 +0.35 (+0.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Ligand Reports First Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
Via Benzinga
Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
Via Benzinga
Ligand Pharmaceuticals Earnings Preview
Via Benzinga
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Fourth Quarter Financial Results on February 22
From Ligand Pharmaceuticals Incorporated
Via Business Wire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... 
Via Benzinga
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says
Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13. 
Via Benzinga
Ligand Pharma Issues Mixed Guidance For FY23
At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its... 
Via Benzinga
Ligand Provides Highlights from its Investor and Analyst Day Event
From Ligand Pharmaceuticals
Via Business Wire
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Hold Investor and Analyst Day on December 13
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Third Quarter 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Earnings Outlook For Ligand Pharmaceuticals
Ligand Pharmaceuticals (NASDAQ:LGND) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Ligand... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million. 
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
Ligand Announces Completion of OmniAb Spin-Off
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Distribution of OmniAb Complete and Business Combination Closed
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Third Quarter Financial Results on November 7
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
OmniAb Business Combination Approved by APAC Shareholders
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.